To provide a comprehensive overview of the current state of IDH-mutant glioma research, including diagnostic challenges, treatment strategies, and long-term patient care.
Approach:
Integrated Diagnosis: Incorporates molecular markers and histology to reshape classification and prognostic stratification of lower-grade gliomas.
Emerging Treatment Strategies: Focus on IDH inhibitors and non-invasive assessment methods like liquid biopsies and deep learning frameworks.
Multidisciplinary Management: Involves collaboration among neurosurgeons, neuro-oncologists, and other specialists to optimize patient care.
Key Findings:
IDH1/2 mutations are associated with improved survival and better response to alkylating agents.
Residual tumor volume and CDKN2A/B homozygous deletions are key prognostic factors.
Traditional prognostic indicators need reassessment in light of molecular advancements.
Interpretation:
The integration of molecular markers into clinical practice is essential for improving prognostic accuracy and treatment decisions in IDH-mutant gliomas.
Limitations:
Current prognostic criteria do not fully incorporate molecular markers.
Limited quantitative evidence supporting the benefits of multidisciplinary care models.
Conclusion:
Advances in molecular biology, imaging, and treatment highlight the need for improved prognostic modeling and clinical integration.
